Comment
Prostate-specific antigen doubling time: a potential surrogate end point in hormone-refractory prostate cancer
- PMID: 10334558
Item in Clipboard
Comment
Prostate-specific antigen doubling time: a potential surrogate end point in hormone-refractory prostate cancer
J Clin Oncol.
1999 May.
No abstract available
Comment on
-
Apples and oranges: building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials.J Clin Oncol. 1998 Oct;16(10):3398-405. doi: 10.1200/JCO.1998.16.10.3398. J Clin Oncol. 1998. PMID: 9779719
Similar articles
-
Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice.J Urol. 2000 May;163(5):1481-5. J Urol. 2000. PMID: 10751862
-
Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing?J Clin Oncol. 2005 Nov 1;23(31):8124-5; author reply 8125-6. doi: 10.1200/JCO.2005.03.2458. J Clin Oncol. 2005. PMID: 16258115 No abstract available.
-
Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.Oncologist. 2005;10 Suppl 3:30-9. doi: 10.1634/theoncologist.10-90003-30. Oncologist. 2005. PMID: 16368869 Review.
-
Prostate specific antigen in as a dynamic model in advanced prostate cancer.Anticancer Res. 2000 Nov-Dec;20(6D):4985-7. Anticancer Res. 2000. PMID: 11326653
-
[The study landscape for prostate cancer].Urologe A. 2005 Dec;44(12):1431-4. doi: 10.1007/s00120-005-0951-0. Urologe A. 2005. PMID: 16292461 Review. German.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical